EHA 2026: Legend Biotech CEO Ying Huang discusses the company's late-breaking in vivo CAR-T presentation showing a 6/6 overall response and 5/6 complete response at the highest dose level in NHL

Jun 14
1 min read

LB2501 is a CD19/CD20 dual targeting CAR-T. He discusses the EHA data, and next steps for the program. Plus, a review of last week's DLL3 data from ASCO and how he thinks about partnering and the competitive landscape.

https://vimeo.com/1200980234

Recent Posts

See All

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month

San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes

EHA 2026: Legend Biotech CEO Ying Huang discusses the company's late-breaking in vivo CAR-T presentation showing a 6/6 overall response and 5/6 complete response at the highest dose level in NHL

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight